Ahmet Sezer, MD, professor, Department of Medical Oncology, Başkent University, Adana, Turkey, discusses the FDA approval of cemiplimab-rwlc (Libtayo) as frontline treatment for patients with advanced non–small cell lung cancer (NSCLC) and high PD-L1 expression.